Mounjaro vs Ozempic — Which One Works Better?

Inception Point AI
  • 0.0 (0)
  • Medicine

The SURMOUNT-5 trial just settled the debate: tirzepatide delivered 47% more weight loss than semaglutide in the first major head-to-head study. Dr. Ben Synth analyzes the science behind dual-agonist therapy, dissects the real-world data, and explores what this means for patients choosing between these blockbuster medications. For more content like this, visit QuietPlease.ai This content was created in partnership and with the help of Artificial Intelligence AI.

Episodes

  1. Apr 7

    Mounjaro vs Ozempic — Which One Works Better? - Weigh the evidence with Dr. Ben Synth

    Join Dr. Ben Synth as he breaks down the landmark clinical trial pitting tirzepatide against semaglutide, revealing why dual-hormone targeting may outperform single-hormone approaches for weight loss. Discover the real science behind cardiovascular benefits, quality of life improvements, and side effects that headlines ignore. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

    1 min

  2. Apr 7

    Mounjaro vs Ozempic — Which One Works Better? - Beyond the Scale

    Host Ben Synth explores the SURMOUNT-5 trial comparing tirzepatide and semaglutide beyond weight loss numbers. Discover how tirzepatide showed earlier cardiovascular risk reduction, better physical quality-of-life scores, and comparable tolerability—but neither drug improved mental health measures. This deep dive examines what really matters when choosing obesity medications. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

    22 min

  3. Apr 7

    Mounjaro vs Ozempic — Which One Works Better? - One Hormone vs Two: Why Tirzepatide Wins

    Ben Synth explores why Mounjaro outperforms Ozempic for weight loss by activating two gut hormones instead of one. Drawing on SURMOUNT-5 trial data showing 20% versus 14% weight loss, he traces GIP's journey from forgotten molecule to metabolic game-changer, revealing how dual-receptor targeting creates synergistic effects that reshape obesity pharmacology's future. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

    27 min

  4. Apr 7

    Mounjaro vs Ozempic — Which One Works Better? - The SURMOUNT-5 Verdict

    Dr. Ben Synth unpacks the SURMOUNT-5 trial, the first head-to-head comparison of tirzepatide and semaglutide for weight loss. Tirzepatide produced 47% more weight loss—20.2% versus 13.7%—in this 72-week study of 751 adults without diabetes. He examines trial design, secondary endpoints, limitations, and what these results mean for patients choosing between the most talked-about drugs in modern medicine. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

    22 min

Trailer

About

The SURMOUNT-5 trial just settled the debate: tirzepatide delivered 47% more weight loss than semaglutide in the first major head-to-head study. Dr. Ben Synth analyzes the science behind dual-agonist therapy, dissects the real-world data, and explores what this means for patients choosing between these blockbuster medications. For more content like this, visit QuietPlease.ai This content was created in partnership and with the help of Artificial Intelligence AI.

Information

You Might Also Like